These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1397029)

  • 1. Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum.
    Rostène W; Boja JW; Scherman D; Carroll FI; Kuhar MJ
    Eur J Pharmacol; 1992 Jul; 218(1):175-7. PubMed ID: 1397029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
    Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
    J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.
    Lee LC; Vander Borght T; Sherman PS; Frey KA; Kilbourn MR
    J Med Chem; 1996 Jan; 39(1):191-6. PubMed ID: 8568807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
    Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.
    Kish SJ; Guttman M; Robitaille Y; el-Awar M; Chang LJ; Levey AI
    Neurology; 1997 Apr; 48(4):1109-11. PubMed ID: 9109912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.
    Vaccari A; Del Zompo M; Melis F; Gessa GL; Rossetti ZL
    Br J Pharmacol; 1991 Nov; 104(3):573-4. PubMed ID: 1797320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding.
    Wall SC; Innis RB; Rudnick G
    Mol Pharmacol; 1993 Feb; 43(2):264-70. PubMed ID: 8429827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
    Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [125I]RTI-55: a potent ligand for dopamine transporters.
    Boja JW; Patel A; Carroll FI; Rahman MA; Philip A; Lewin AH; Kopajtic TA; Kuhar MJ
    Eur J Pharmacol; 1991 Feb; 194(1):133-4. PubMed ID: 2060590
    [No Abstract]   [Full Text] [Related]  

  • 13. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine rapidly decreases vesicular dopamine uptake.
    Brown JM; Hanson GR; Fleckenstein AE
    J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 2-substituted cocaine analogs: binding properties at dopamine transport sites in rat striatum.
    Davies HM; Saikali E; Sexton T; Childers SR
    Eur J Pharmacol; 1993 Jan; 244(1):93-7. PubMed ID: 8420793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.
    Wilson JM; Kish SJ
    J Neurosci; 1996 May; 16(10):3507-10. PubMed ID: 8627383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a single dopamine transporter cDNA can confer two cocaine binding sites.
    Boja JW; Markham L; Patel A; Uhl G; Kuhar MJ
    Neuroreport; 1992 Mar; 3(3):247-8. PubMed ID: 1515577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotransmitter transporters synthesis and degradation rates.
    Kimmel H; Vicentic A; Kuhar MJ
    Life Sci; 2001 Apr; 68(19-20):2181-5. PubMed ID: 11358326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microheterogeneity of dopamine transporters in rat striatum and nucleus accumbens.
    Lew R; Patel A; Vaughan RA; Wilson A; Kuhar MJ
    Brain Res; 1992 Jul; 584(1-2):266-71. PubMed ID: 1515945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple binding sites for [125I]RTI-121 and other cocaine analogs in rat frontal cerebral cortex.
    Boja JW; Carroll FI; Vaughan RA; Kopajtic T; Kuhar MJ
    Synapse; 1998 Sep; 30(1):9-17. PubMed ID: 9704876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.